Voltage-Dependent Anion Channel 1 As an Emerging Drug Target for Novel Anti-Cancer Therapeutics
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Cancer cells share a common set of properties, including unlimited proliferation potential, self-sufficiency in terms of growth signals, and resistance to anti-proliferative and apoptotic cues. Acquiring these hallmarks involves changes in key oncogenes and non-oncogenes essential for cancer cell survival and prosperity, and is accompanied by the increased energy requirements of proliferating cells. Mitochondria occupy a central position in cell life and death with mitochondrial bioenergetics, biosynthesis, and signaling are critical for tumorigenesis. Voltage-dependent anion channel 1 (VDAC1) is situated in the mitochondrial outer membrane (OMM) and serving as a mitochondrial gatekeeper. VDAC1 allowing the transfer of metabolites, ions, Ca2+, ROS and cholesterol across the OMM and is a key player in mitochondrial-mediate apoptosis. Moreover, VDAC1 serves as a hub protein, interacting with diverse sets of proteins from the cytosol, endoplasmic reticulum, and mitochondria that together regulate metabolic and signaling pathways. The observation that VDAC1 is over-expressed in many cancers suggests that the protein may play a pivotal role in cancer cell survival. However, VDAC is also important in mitochondria-mediated apoptosis, mediating release of apoptotic proteins and interacting with anti-apoptotic proteins such as Bcl-2, Bcl-xL, and hexokinase, which are also highly expressed in many cancers. Strategically located in a “bottleneck” position, controlling metabolic homeostasis and apoptosis, VDAC1 thus represents an emerging target for anti-cancer drugs. This review presents an overview on VDAC1 as a multi-functional mitochondrial protein, regulating both cell life and death, and highlights the importance of the protein for cancer cell survival. We address recent results related to the mechanisms of VDAC1-mediated apoptosis and the potential of associated proteins to modulate of VDAC1 activity, with the aim of developing VDAC1-based strategies to attack the altered metabolism and/or to activate apoptosis of cancer cells. These strategies include siRNA able to impair energy and metabolic homeostasis, leading to arrested cancer cell growth, inhibited tumor growth and reversed oncogenic properties, as well as VDAC1-based peptides that interact with anti-apoptotic proteins to induce apoptosis. Finally, we discuss the potential therapeutic benefits of treatments and drugs leading to enhanced VDAC1 expression or targeting VDAC1 to induce apoptosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A role for mitochondria in nlrp3 inflammasome activation
Zhou, R., Yazdi, A. S., Menu, P., & Tschopp, J. (2011) · Nature · doi:10.1038/nature09663 · Cited by 5,602
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744 · cited 1×
“Cancer cells exhibit significant metabolic alterations with respect to several critical substrates, including important changes in the metabolism of both glucose and glutamine that require plasticity of the metabolic machinery (107, 108).”
BackgroundThe Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032 · cited 1×
“The intrinsic pathway is regulated by members of the B-cell lymphoma 2 (Bcl-2) family of proteins (125), and by the inhibitor of apoptosis protein (IAP) family of proteins (126).”
BackgroundMitochondrial membrane permeabilization in cell death
Kroemer, G., Galluzzi, L., & Brenner, C. (2007) · Physiological Reviews · doi:10.1152/physrev.00013.2006 · Cited by 3,598 · cited 6×
“The AIF released is translocated to the nucleus, leading to chromatin condensation and DNA fragmentation (124).”
BackgroundInfluentialOtto Warburg's contributions to current concepts of cancer metabolism
Koppenol, W. H., Bounds, P. L., & Dang, C. V. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3038 · Cited by 3,427
Cancer cell metabolism: warburg and beyond
Hsu, P. P., & Sabatini, D. M. (2008) · Cell · doi:10.1016/j.cell.2008.08.021 · Cited by 2,452
Baines, C. P., Kaiser, R. A., Purcell, N. H., Blair, N. S., Osinska, H., Hambleton, M. A., Brunskill, E. W., Sayen, M. R., Gottlieb, R. A., Dorn, G. W., et al. (2005) · Nature · doi:10.1038/nature03434 · Cited by 2,280 · cited 1×
“However, in knockout experiments performed in mice, even mitochondria examined from cells lacking some but not all ANT isoforms (148, 149), or VDAC1 (150) showed PTP formation.”
BackgroundShimizu, S., Narita, M., Tsujimoto, Y., & Tsujimoto, Y. (1999) · Nature · doi:10.1038/20959 · Cited by 2,178 · cited 3×
“Evidence supporting the activity of VDAC1 in apoptosis includes (a) Cyto c release, cell death, and Bax–VDAC1 interaction were all inhibited by anti-VDAC1 antibodies (135–137); (b) HK-I and HK-II interacting with VDAC1 inhibited staurosporine (STS)-induced Cyto c release and apoptosis in native but not mutated VDAC1-e…”
BackgroundMitochondrial dysfunction and type 2 diabetes
Lowell, B. B., & Shulman, G. I. (2005) · Science · doi:10.1126/science.1104343 · Cited by 2,070
RAS–RAF–MEK-dependent oxidative cell death involving voltage-dependent anion channels
Yagoda, N., von Rechenberg, M., Zaganjor, E., Bauer, A. J., Yang, W. S., Fridman, D. J., Wolpaw, A. J., Smukste, I., Peltier, J. M., Boniface, J. J., et al. (2007) · Nature · doi:10.1038/nature05859 · Cited by 1,631
Cited by
VDAC1, mitochondrial dysfunction, and Alzheimer’s disease
Shoshan-Barmatz, V., Nahon-Crystal, E., Shteinfer-Kuzmine, A., & Gupta, R. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.03.010 · Cited by 286
Self-citationAutophagy and mitophagy in cancer metabolic remodelling
Ferro, F., Servais, S., Besson, P., Roger, S., Dumas, J.-F., & Brisson, L. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.05.029 · Cited by 281
Zhang, E., Mohammed Al-Amily, I., Mohammed, S., Luan, C., Asplund, O., Ahmed, M., Ye, Y., Ben-Hail, D., Soni, A., Vishnu, N., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.09.008 · Cited by 171
“VDAC1 is a target in cancer therapy (Shoshan-Barmatz et al., 2017) and”
BackgroundER-mitochondria interactions: Both strength and weakness within cancer cells
Doghman-Bouguerra, M., & Lalli, E. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.01.009 · Cited by 94
Metadata
- Authors
- Shoshan-Barmatz, V., Krelin, Y., Shteinfer-Kuzmine, A., & Arif, T.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2017-07-31
- Volume
- 7
- Pages
- 154-154
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2732956904
- Cited by
- 133
- References
- 46
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.